Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Objectives: Evaluation of the feasibility of SARS-CoV-2-specific T cell manufacturing for adoptive T cell transfer in COVID-19 patients at risk to develop severe disease.Methods: Antiviral SARS-CoV-2-specific T cells were detected in blood of convalescent COVID-19 patients following stimulation with...

Full description

Bibliographic Details
Main Authors: Agnes Bonifacius, Sabine Tischer-Zimmermann, Maria Michela Santamorena, Philip Mausberg, Josephine Schenk, Stephanie Koch, Johanna Barnstorf-Brandes, Nina Gödecke, Jörg Martens, Lilia Goudeva, Murielle Verboom, Jana Wittig, Britta Maecker-Kolhoff, Herrad Baurmann, Caren Clark, Olaf Brauns, Martina Simon, Peter Lang, Oliver A. Cornely, Michael Hallek, Rainer Blasczyk, Dominic Seiferling, Philipp Köhler, Britta Eiz-Vesper
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
adoptive T cell therapy
antiviral T cells
immunotherapy
SARS-CoV-2
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fbioe.2022.867042/full

Internet

https://www.frontiersin.org/articles/10.3389/fbioe.2022.867042/full

Similar Items